77813-61-7

Upstream product

• 68786-47-0 (Z)-2-(trityloxyimino)-2-(2-tritylamino-4-thiazolyl)acetic acid 

Downstream Products

• 153502-32-0 p-nitrobenzyl (7S,6R)-7-<<2-<(tritylamino)-4-thiazolyl>trityloximinoacetyl>amino>-3-chloro-1-carba-1-dethia-3-cephem-4-carboxylate 
• 153502-31-9 p-nitrobenzyl (7S,6R)-7-<<2-<(tritylamino)-4-thiazolyl>trityloximinoacetyl>amino>-3-chloro-3-cephem-4-carboxylate 
• 153502-35-3 (7S,6R)-7-<<(2-amino-4-thiazolyl)hydroximinoacetyl>amino>-3-chloro-1-carba-1-dethia-3-cephem-4-carboxylic acid 
• 153502-34-2 (7S,6R)-7-<<2-<(tritylamino)-4-thiazolyl>trityloximinoacetyl>amino>-3-chloro-1-carba-1-dethia-3-cephem-4-carboxylic acid 
• 153502-33-1 (7S,6R)-7-<<2-<(tritylamino)-4-thiazolyl>trityloximinoacetyl>amino>-3-chloro-3-cephem-4-carboxylic acid 

Relevant academic research and scientific papers

Stable bioavailable crystalline form or cefdinir and a process for the preparation thereof

The present invention relates to a stable and bioavailable crystalline form of a third generation cephalosporin antibiotic, cefdinir and a process for the preparation thereof. The present invention also relates to a pharmaceutical composition containing the novel crystalline cefdinir, useful in the treatment of maladies such as bacterial infections.